NCT07315672 Acupressure for Cough in Lung Cancer Survivors
| NCT ID | NCT07315672 |
| Status | Recruiting |
| Phase | — |
| Sponsor | The University of Hong Kong |
| Condition | Lung Cancer (Diagnosis) |
| Study Type | INTERVENTIONAL |
| Enrollment | 80 participants |
| Start Date | 2026-03-09 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 80 participants in total. It began in 2026-03-09 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this randomized controlled trial is to examine the effect of an acupressure intervention in alleviating cough and reducing co-occurring symptoms (dyspnea, cough, and fatigue) in patients with lung cancer. The hypotheses are: 1. Acupressure can alleviate cough in lung cancer survivors; 2. Acupressure can reduce a cough-related symptom cluster (dyspnea-cough-fatigue) experienced by lung cancer survivors; 3. Acupressure can reduce the symptom burden and improve the health-related quality of life and functional capacity of lung cancer survivors experiencing cough. Participants will: Receive acupressure for 8 weeks or receive an education booklet; Keep a diary of their acupressure practice and symptoms; Be assessed at baseline (T0), early intervention (T1), post-intervention (T2), and 8 weeks after the intervention period (T3).
Eligibility Criteria
Inclusion Criteria: * be at least 18 years of age; * have a diagnosis of LC at any stage and of any pathological type; * have a cough symptom rating ≥3 on a 0 to 10 numeric rating scale within 7 days preceding enrollment; * can perform acupressure independently in daily activities; * be able to read Chinese and communicate in Cantonese or Mandarin; * be able to provide informed consent. Exclusion Criteria: * have unstable chronic diseases other than LC; * have received acupressure or acupuncture within the three months preceding study enrollment; * have serious illnesses or other conditions that prevent the participants from following the intervention protocols; * have a life expectancy of less than 3 months; * Be currently participating in other research programs that may affect the outcomes under investigation.
Contact & Investigator
Denise Shuk Ting Cheung, PhD
STUDY DIRECTOR
The University of Hong Kong
Frequently Asked Questions
Who can join the NCT07315672 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Lung Cancer (Diagnosis). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07315672 currently recruiting?
Yes, NCT07315672 is actively recruiting participants. Contact the research team at u3590805@connect.hku.hk for enrollment information.
Where is the NCT07315672 trial being conducted?
This trial is being conducted at Shenzhen, China, Hong Kong, Hong Kong.
Who is sponsoring the NCT07315672 clinical trial?
NCT07315672 is sponsored by The University of Hong Kong. The principal investigator is Denise Shuk Ting Cheung, PhD at The University of Hong Kong. The trial plans to enroll 80 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.